Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 1-year safety study of tasimelteon 20 mg in blind individuals with Non-24-Hour Sleep-Wake Disorder
2010-020912-12Phase 3Active
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tasimelteon in Non-24-hour sleep-wake disorder (N24SWD) and circadian rhythm sleep disorder (CRSD), sponsored by Vanda Pharmaceuticals Inc. Primary endpoint: Safety endpoints. Started Jul 2010; status: active.
02
Drugs
tasimelteon
03
Conditions
Non-24-hour sleep-wake disorder (N24SWD)circadian rhythm sleep disorder (CRSD)
Beyond the preview
Go deeper on 2010-020912-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020912-12.